Share this article
NEW YORK, Feb. 10, 2021 /PRNewswire/
Scopus BioPharma Inc. (Nasdaq: SCPS) today announced the closing of the underwriters over-allotment option in full, bringing total follow-on public offering proceeds to $10.35 million.
Scopus is a biopharmaceutical company developing transformational therapeutics based on groundbreaking scientific and medical discoveries. The company s lead drug candidate is a novel, targeted immuno-oncology gene therapy for the treatment of multiple cancers.
Scopus intends to use the total proceeds of the follow-on public offering, including the proceeds from the exercise of the over-allotment option, principally for further development of the company s lead drug candidate, including in combination with checkpoint inhibitors.
Press release content from PR Newswire. The AP news staff was not involved in its creation.
Underwriters Exercise Over-Allotment Option in Full, Brings Total Follow-On Public Offering Proceeds to $10.35 Million
February 9, 2021 GMT
(PRNewsfoto/Scopus BioPharma Inc.)
NEW YORK, Feb. 8, 2021 /PRNewswire/ Scopus BioPharma Inc. (Nasdaq: SCPS) today announced that the underwriters of the company’s follow-on public offering exercised their over-allotment option in full, bringing total proceeds to $10.35 million.
The exercise of the over-allotment option is expected to close on or about February 10, 2021, subject to customary closing conditions.
Scopus is a biopharmaceutical company developing transformational therapeutics based on groundbreaking scientific and medical discoveries. The company’s lead drug candidate is a novel, targeted immuno-oncology gene therapy for the treatment of multiple cancers.
Scopus BioPharma Announces Closing of Initial Public Offering
Underwriters Exercise Over-Allotment Option in Full
IPO Proceeds for Further Development of Company s Novel, Targeted Immuno-Oncology Gene Therapy for Multiple Cancers
News provided by
Share this article
NEW YORK, Dec. 18, 2020 /PRNewswire/
Scopus BioPharma Inc. (Nasdaq: SCPS) today announced the closing of its initial public offering. The underwriters for the initial public offering exercised their over-allotment option in full.
The company offered 575,000 shares of common stock, including shares issued for the over-allotment option, at a public offering price of $5.50 per share.
The company s common stock trades on the Nasdaq Global Market under the ticker symbol SCPS .